加州聖卡洛斯–(BUSINESS WIRE)–(美國商業資訊)– 全球性腫瘤公司BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235)今日在10月23日至27日於馬德里舉行的2026年歐洲腫瘤內科學會(ESMO)大會上，公布了其重點實質腫瘤疾病領域多款差異化試驗中藥物的最新數據。報告涵蓋胃腸道腫瘤、肺癌和乳癌，體現了BeOne實質腫瘤業務不斷強化的發展動力。 BeOne實質腫瘤醫療長Mark Lanasa, M.D.博士表示： 「在本次ESMO大會上，我們展示了將合適的治療方式與疾病生物學特徵相匹配的策略如何轉化為有意義的臨床進展。我們的GPC3 x 4-1BB雙特異性抗體在重度經治肝細胞癌(HCC)病患中繼續表現出良好的耐受性，並在更長隨訪期下展現出持久活性；同時，具有腦滲透能力的PRMT5抑制劑和標靶作用於CEA之ADC的首次臨床數據，進一步擴大了我們在非小細胞肺癌領域的創新布局。結合我們在乳癌領域展開的CDK4抑制劑全球第三期KANDELA-302研究，這些進展代表BeOne實質腫瘤研發產品線正從有前景的科學
Author: sHq_LoGiNz
MIAMI–(BUSINESS WIRE)—- $SMMT–Summit Therapeutics Inc. (Nasdaq: SMMT) today noted that its partner Akeso Inc. announced positive results from the Phase III HARMONi-GI1 study evaluating the novel, potential first-in-class investigational bispecific antibody ivonescimab plus chemotherapy compared with durvalumab plus chemotherapy as a first-line treatment for patients with advanced biliary tract cancer (BTC). These data are featured in today’s Presidential Symposium II at the European Society for Medic
WILMINGTON, Del.–(BUSINESS WIRE)–Positive results from the CLARITY-Gastric01 global Phase III trial showed AstraZeneca’s sonesitatug vedotin (Sone-Ve) demonstrated a statistically significant and highly clinically meaningful improvement in overall survival (OS) in 2nd- and later-line Claudin 18.2-positive advanced gastric cancers versus investigator’s choice of therapy. The trial included patients with locally advanced or metastatic gastric cancer, gastroesophageal junction (GEJ) cancer, or e
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)—- $RHHBY–Divarasib demonstrated best-in-class efficacy in Phase III trial, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer
WILMINGTON, Del.–(BUSINESS WIRE)–Positive results from the SAFFRON Phase III trial showed TAGRISSO® (osimertinib) plus savolitinib demonstrated a statistically significant and clinically meaningful improvement in both progression-free survival (PFS) and overall survival (OS) versus doublet platinum-based chemotherapy in patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). Patients in the trial had tumors with high levels of MET overexpression or a
NEW YORK–(BUSINESS WIRE)–Rosen Law Firm, a global investor rights law firm, reminds investors about a class action on behalf of purchasers of securities of Hims & Hers Health, Inc. (NYSE: HIMS) between August 4, 2025 and July 29, 2026. Hims describes itself as a company that “operates a health and wellness platform that connects consumers to licensed healthcare professionals.”For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653.The Allegations:
LEXINGTON, Mass.–(BUSINESS WIRE)—- $AGEN #AGEN–Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced early Phase 2 results from the mismatch repair-deficient (dMMR) colon cancer cohort of NEOASIS, an investigator-initiated pan-tumor study sponsored by the Netherlands Cancer Institute (NKI). NEOASIS is evaluating botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody, given before surgery
COPENHAGEN, Denmark–(BUSINESS WIRE)–Genmab A/S (Nasdaq: GMAB) today announced updated follow-up analyses from a Phase 2 trial evaluating petosemtamab, an investigational IgG1-bispecific antibody targeting the epidermal growth factor receptor (EGFR) and leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5), in combination with FOLFOX or FOLFIRI in patients with metastatic colorectal cancer (mCRC). At a median follow-up of 5.9 months in the first-line (1L) setting and 7.1 months in
カリフォルニア州サンカルロス–(BUSINESS WIRE)–（ビジネスワイヤ） — BeOne Medicines Ltd.（Nasdaq：ONC、HKEX：06160、SSE：688235）は、グローバルなオンコロジー企業であり、重点を置く固形腫瘍領域で開発する複数の差別化された治験薬について、「欧州臨床腫瘍学会（ESMO）2026年大会」（10月23～27日、マドリード）で新たなデータを発表しました。発表は消化器がん、肺がん、乳がんに及び、BeOneの固形腫瘍事業が勢いを増していることを示しています。 BeOneの固形腫瘍部門最高医学責任者であるマーク・ラナサ医学博士・哲学博士は、次のように述べています。 「ESMOでは、疾患の生物学的特性に応じて適切なモダリティーを選択するという当社の戦略が、意義ある臨床的進展につながっていることを示しています。当社のGPC3×4-1BB二重特異性抗体は、前治療歴の多い肝細胞がん（HCC）患者において、より長期の追跡でも引き続き良好な忍容性を示し、持続的な活性が認められています。また、当社の脳透過性PRMT5阻害薬とCEA標的ADCの初
加州聖卡洛斯–(BUSINESS WIRE)–(美國商業資訊)– 全球性腫瘤公司BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235)今日公布了HERIZON-GEA-01第三期試驗計畫內的第二次期中分析(IA2)及最終正式分析的最新生存結果，進一步證實TEVIMBRA® (tislelizumab)聯合ZIIHERA® (zanidatamab)及化療做為HER2陽性局部晚期或移轉性胃食管腺癌(GEA)病患一線治療的獲益。這些結果將於今日在西班牙馬德里舉行的2026年歐洲腫瘤內科學會(ESMO)大會的快速口頭報告環節以最新突破性摘要形式公布(LBA79)。 BeOne實質腫瘤醫療長Mark Lanasa, M.D.博士表示： 「繼今年8月獲得美國核准後，這些更長期的數據進一步證實TEVIMBRA聯合ZIIHERA及化療可做為所有一線HER2陽性晚期胃食管腺癌病患的新基準治療方案，無論PD-L1狀態如何。相較於trastuzumab聯合化療，TEVIMBRA聯合ZIIHERA及化療此前所展現的生存獲益幅度在更長隨訪